Menu
Recruiting NCT06956391

Ultralow Dose PET Imaging of 18F-FDG Uptake

Phase II Interventional Healthy Volunteer Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: 18F-FDG.
Who it may be relevant to
Registry conditions: Healthy Volunteer, Cancer. Basic parameters: 18 years — 120 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Evaluation of Ultralow Dose PET Imaging for Detecting 18F-FDG Uptake

Overview

The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for cancer detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called 18F-FDG and be imaged on a new type of high-sensitivity PET scanner for up to 3 hours.

Detailed description

This research study aims to evaluate an investigational ultralow dose PET imaging technique for cancer detection and monitoring. "Investigational" means that the procedure or drug being studied is not yet approved by the FDA for the specific use being tested in this research. The PET imaging technique used in this study is considered investigational because it is being tested at an ultralow radiation dose that has not yet been approved for clinical use. The radiotracer, 18F-FDG, is FDA-approved for detecting cancer at standard doses.

18F-FDG is often found to be taken up at higher levels in cancer. In this study, investigators will use a very small amount of this tracer (less than 1/20th of the standard dose) along with advanced PET imaging technology to see if it is possible to create clear images while using much less radiation. This study aims to develop a safer imaging technique that could potentially be used more frequently for screening and monitoring cancer.

Investigators will enroll individuals with and without cancer to evaluate how ultralow dose PET imaging detects 18F-FDG uptake in different types of tissue.

Approximately 200 people will be enrolled in this study at the Nuclear Imaging Institute.

Interventions

  • Drug 18F-FDG
    Participants will be injected with 18F-FDG and imaged for up to 3 hours on a PET scanner

Primary outcome measures

  • Signal-to-Noise Ratio (SNR) [Time frame: Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period.]
  • Contrast-to-Noise Ratio (CNR) [Time frame: Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period.]
  • Coefficient of Variation (COV) [Time frame: Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period.]
  • Spatial Resolution (Full Width at Half Maximum - FWHM) [Time frame: Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period.]
  • Target-to-Background Ratio (TBR) [Time frame: Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period.]
  • Qualitative Image Quality Score (Likert Scale) [Time frame: Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period.]
  • Inter-reader Agreement (Weighted Kappa Statistics) [Time frame: Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period.]

Eligibility criteria

Inclusion criteria

  • Age ≥18 years.
  • Ability to provide informed consent and comply with study procedures.
  • For female participants:
  • Must not be pregnant or breastfeeding.
  • Negative pregnancy test required for women of childbearing potential.

Exclusion criteria

  • Participants who have exceeded NRC regulation for annual radiation exposure from prior research-related scans, including this study (50 mSv total).
  • More than four prior enrollments in this study.
  • Participants with severe claustrophobia, chronic pain, or musculoskeletal conditions that prevent completion of the PET scan
  • Medication \& Prior Treatment Exclusions
  • Pregnant or breastfeeding individuals (negative pregnancy test required)
  • Inability to provide informed consent
  • Any condition that, in the investigator's judgment, may compromise participant safety or study integrity.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Diagnostic

Study locations

United States · 1 center
  • Nuclear Imaging Institute — Englewood

Identifiers

NCT: NCT06956391 · NII-0002-FDG

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗